56 results match your criteria: "Tokyo Bay Medical Center[Affiliation]"
Cardiovasc Intervent Radiol
December 2024
Department of Cardiology, Tokyo Bay Medical Center, 3-4-32, Todaijima, Urayasu, Chiba, 279-0001, Japan.
EuroIntervention
September 2024
Cardiovascular Center, Kansai Rosai Hospital, Amagasaki, Japan.
Background: Although femoropopliteal-specific stents have durable patency, stent thrombosis (ST) may occur, which can lead to acute limb ischaemia (ALI).
Aims: We aimed to investigate the clinical features and outcomes of ALI caused by femoropopliteal ST in patients with lower extremity artery disease.
Methods: This multicentre retrospective study included 499 patients with ALI - of whom 108 patients had ALI caused by femoropopliteal ST (ST-ALI) and 391 patients had ALI caused by other aetiologies (de novo ALI) - who underwent treatment between September 2011 and March 2023.
Minerva Cardiol Angiol
October 2024
Department of Cardiology, Tokyo Bay Medical Center, Urayasu, Japan.
Background: Degenerative severe aortic valve stenosis (AS) is increasingly prevalent in the aging population, leading to the adoption of transcatheter aortic valve replacement (TAVR) as a less invasive alternative. While TAVR indications have expanded, the procedure is associated with a substantial incidence of major adverse cardiac events (MACE). The study aims to establish a preoperative risk-stratification system for TAVR candidates based on Sokolow-Lyon voltage (SLV) and other relevant factors.
View Article and Find Full Text PDFJ Card Fail
September 2024
Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan; Japan Agency for Medical Research and Development-Core Research for Evolutionary Medical Science and Technology (AMED-CREST), Japan Agency for Medical Research and Development, Tokyo, Japan.
J Endovasc Ther
August 2024
Division of Vascular Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Background: Previous reports have shown comparable outcomes between drug-eluting stents (DESs) and drug-coated balloons (DCBs) for treating femoropopliteal artery (FPA) lesions; however, DCB outcomes include approximately 10% to 50% bailout stents. Therefore, comparing DESs and DCBs is not simple. The aim of this study was to compare the clinical outcomes of DESs and DCBs in patients with symptomatic FPA disease.
View Article and Find Full Text PDFJ Cardiol Cases
August 2024
Department of Cardiology, Tokyo Bay Medical Center, Urayasu, Japan.
PLoS One
August 2024
Department of Cardiovascular Medicine, The University of Tokyo Hospital, Tokyo, Japan.
Ther Apher Dial
October 2024
Department of Nephrology, Endocrinology, and Diabetes, Tokyo Bay Medical Center, Urayasu, Japan.
JACC Adv
November 2023
Department of Cardiology, Tokai University School of Medicine, Isehara, Japan.
Catheter Cardiovasc Interv
August 2024
Division of Cardiology, Teikyo University Hospital, Tokyo, Japan.
Background: Although technological improvements in intravascular ultrasound (IVUS) may reduce technical failures in endovascular therapy (EVT), perioperative complications (POCs) associated with IVUS use may increase.
Aims: This study investigated the impact of IVUS on periprocedural outcomes in symptomatic lower-extremity artery disease (LEAD) patients undergoing EVT.
Methods: This study evaluated 28,088 symptomatic LEAD patients who underwent EVT between January 2021 and December 2021 using a prospective nationwide registry in Japan.
Cardiovasc Intervent Radiol
June 2024
Division of Minimally Invasive Treatment in Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo, Japan.
Purpose: In the present trial, the 24-month safety and effectiveness of the TCD-17187 drug-coated balloon (DCB) for the treatment of atherosclerotic lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PA) were evaluated in Japanese patients.
Methods: This was a prospective, multicenter, core laboratory-adjudicated, single-arm trial. From 2019 to 2020, 121 patients with symptomatic peripheral artery disease were enrolled.
Vasc Med
August 2024
Department of Radiology and IVR Center, Nara Medical University, Nara, Japan.
The safety and effectiveness of the GORE VIABAHN Endoprosthesis for treatment of symptomatic patients with peripheral artery disease (PAD) and complex femoropopliteal (FP) lesions was assessed in a real-world Japanese practice setting. : A prospective, multicenter, postmarket surveillance study was conducted from 2016 to 2017 at 64 sites in Japan. Symptomatic patients with PAD and FP lesions ⩾ 10 cm and reference vessel diameters ranging from 4.
View Article and Find Full Text PDFJ Endovasc Ther
February 2024
Department of Cardiology, Kishiwada Tokushukai Hospital, Osaka, Japan.
Purpose: Surgical thromboendarterectomy has been the gold standard treatment for common femoral artery (CFA) disease. However, endovascular therapy (EVT) is conducted in certain patients with CFA lesions because of multiple comorbidities. The interwoven nitinol stent (IWS) has been developed to prevent stent fracture.
View Article and Find Full Text PDFJACC Cardiovasc Interv
December 2023
Department of Cardiology, Tokyo Bay Medical Center, Urayasu, Japan.
Catheter Cardiovasc Interv
December 2023
Department of Cardiology, Tokyo Bay Medical Center, Urayasu, Japan.
Below-the-knee (BTK) pseudoaneurysms that occur after endovascular therapy (EVT) and result in delayed rupture have rarely been reported. In this report, we present a rare case of an 86-year-old man with chronic limb-threatening ischemia who developed delayed rupture of an idiopathic pseudoaneurysm of the peroneal artery (PA) following EVT. The PA chronic total occlusion (CTO) was successfully crossed using a guidewire via an antegrade approach, however, subintimal crossing was confirmed by intravascular ultrasound.
View Article and Find Full Text PDFJ Cardiol
April 2024
University of Missouri, Columbia, MO, USA. Electronic address:
Background: Effective and durable options for infrapopliteal artery revascularization for patients with chronic limb-threatening ischemia (CLTI) are limited.
Methods: The SAVAL trial is a prospective, multicenter, randomized trial of patients with CLTI and infrapopliteal artery lesions with total lesion length ⩽ 140 mm, stenosis ⩾ 70%, and Rutherford category 4-5 assigned 2:1 to treatment with the SAVAL self-expandable paclitaxel drug-eluting stent (DES) or percutaneous transluminal angioplasty (PTA) with an uncoated balloon. The primary effectiveness endpoint was primary vessel patency (i.
JACC Cardiovasc Interv
November 2023
Division of Vascular Surgery, Department of Surgery, Jikei University School of Medicine, Tokyo, Japan.
Background: Randomized trials have shown comparable outcomes between second-generation low-dose drug-coated balloons (LD-DCBs) and first-generation high-dose drug-coated balloons (HD-DCBs); but the trial patients had low clinical complexity, and there were no comparisons in medically complex populations.
Objectives: The aim of this study was to compare outcomes between an LD-DCB (Ranger; 2.0 μg/mm) and an HD-DCB (IN.
J Vasc Surg
April 2024
Department of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Department of Cardiology, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY. Electronic address:
Objective: Intravascular ultrasound (IVUS) is an important adjunctive tool for patients with lower extremity peripheral arterial disease (PAD) undergoing endovascular therapy (EVT). The evidence regarding the advantages of IVUS use is evolving, and recent studies have reported conflicting results. We aimed to perform a meta-analysis to evaluate the efficacy of IVUS during angiography-guided EVT for patients with PAD.
View Article and Find Full Text PDFJ Vasc Interv Radiol
November 2023
Department of Cardiology, Saiseikai Fukuoka General Hospital, Fukuoka, Japan.
Purpose: To investigate the 1-year and 2-year clinical outcomes of interwoven stent (IWS) implantation for symptomatic femoropopliteal arterial disease with calcification.
Material And Methods: This prospective multicenter study evaluated 308 limbs (63% with the peripheral arterial calcium scoring system 3 and 4 severe calcification and 87% with ≥180° calcification on intravascular ultrasound) of 299 patients (diabetes in 66.9%, chronic renal failure in 52.
J Endovasc Ther
July 2023
Department of Cardiology, Teikyo University Hospital, Tokyo, Japan.
Purpose: Our objective was to evaluate the feasibility of performing endovascular therapy (EVT) for aortoiliac artery disease using transradial approach (TRA) as compared to transfemoral approach (TFA).
Methods: We analyzed 9671 cases with symptomatic lower extremity artery disease due to aortoiliac occlusive disease (AIOD) treated using EVT from a Japanese Nationwide EVT Registry between January and December 2021. We compared the baseline characteristics, procedural information, and 30-day outcomes of patients who received EVT only via TRA (n=863 [16.
Ther Apher Dial
October 2023
Department of Cardiology, Tokyo Bay Medical Center, Urayasu, Japan.
Introduction: Lipoprotein apheresis (LA) is a possible adjunct treatment for no-option chronic limb-threatening ischemia (CLTI). This study aimed to assess the impact of a novel LA for no-option CLTI.
Methods: We retrospectively assessed 19 patients with no-option CLTI treated using the novel LA.
J Endovasc Ther
April 2023
Department of Cardiology, Funabashi Municipal Medical Center, Funabashi, Japan.
Purpose: To compare the outcomes of thromboendarterectomy (TEA) and endovascular therapy (EVT) with stenting for patients with atherosclerotic common femoral artery (CFA) occlusive disease.
Materials And Methods: From a retrospective registry of 1193 consecutive patients with CFA treatment performed between 2018 and 2020 at 66 institutions in Japan, we identified patients who underwent TEA (n=432) or stent implantation (n=157). The primary outcome measures were the 1-year primary patency of TEA versus stenting with propensity score matching.
Eur J Vasc Endovasc Surg
June 2023
Department of Vascular Surgery, Matsuyama Red Cross Hospital, Ehime, Japan.
Objective: Surgical thromboendarterectomy (TEA) is the standard treatment for an occlusive lesion of the common femoral artery (CFA). However, there is limited knowledge on the need for patch angioplasty in CFA TEA. The objective of this study was to compare the peri-operative and two year results of CFA TEA with or without patch angioplasty.
View Article and Find Full Text PDFCatheter Cardiovasc Interv
April 2023
Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Kishiwada, Osaka, Japan.
Purpose: To investigate whether the severity of calcification assessed by the peripheral artery calcification scoring system (PACSS) was associated with clinical outcomes of drug-coated balloon (DCB) angioplasty for femoropopliteal lesions.
Materials And Methods: We retrospectively analyzed 733 limbs with intermittent claudication of 626 patients, who underwent DCB angioplasty for de novo femoropopliteal lesions between January 2017 and February 2021 at seven cardiovascular centers in Japan. The patients were categorized using the PACSS classification (grades 0-4: no visible calcification of the target lesion, unilateral wall calcification < 5 cm, unilateral calcification ≥ 5 cm, bilateral wall calcification < 5 cm, and bilateral calcification ≥ 5 cm, respectively).